维生素D补充对澳大利亚老年人急性呼吸道感染的影响:D-Health试验分析
该研究基于D-Health随机双盲安慰剂对照试验,分析每月补充维生素D对60-79岁澳大利亚老年人急性呼吸道感染风险、病程和严重程度的影响。
要点
- 日记分析显示症状持续时间略有缩短,但临床意义可能有限。
- 在维生素D充足人群中常规补充对急性呼吸道感染临床相关影响不大。
核心结论
- 每月大剂量维生素D补充未降低急性呼吸道感染总体风险。
- 可能轻微缩短症状持续时间,但临床意义有限。
- 在维生素D充足人群中常规补充不太可能对急性呼吸道感染产生临床相关影响。
研究设计与样本
- 随机、双盲、安慰剂对照试验(D-Health Trial),参与者为60-79岁澳大利亚成年人(志愿者至84岁)。
主要发现
- 日记数据显示症状总持续时间及严重症状持续时间有所缩短,但幅度小且可能无临床意义。
临床怎么用
- 对于维生素D充足的老年人,常规补充维生素D可能不会显著减少急性呼吸道感染。
- 临床决策应个体化,考虑维生素D状态及感染风险。
局限性
- 研究人群主要为维生素D充足者,结果可能不适用于维生素D缺乏人群。
- 调查数据依赖自我报告,可能存在回忆偏倚。
- 日记数据仅来自冬季子样本,可能不能代表全年情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Observational studies have linked vitamin D deficiency with acute respiratory tract infection, but results from randomised controlled trials are heterogeneous. We analysed data from the D-Health Trial to determine whether supplementing older Australian adults, recruited from the general population, with monthly doses of vitamin D reduced the risk, duration, and severity of acute respiratory tract infections. METHODS: We used data from the D-Health Trial, a randomised, double-blind, placebo-controlled trial of monthly vitamin D supplementation, for which acute respiratory infection was a pre-specified trial outcome. Participants were supplemented and followed for up to 5 years. The trial was set within the Australian general population, using the Commonwealth Electoral Roll as the sampling frame, but also allowing some volunteers to participate. Participants were men and women aged 60 to 79 years (with volunteers up to age 84 years). Participants were randomly assigned to receive either vitamin D or placebo (1:1) using computer-generated permuted block randomisation, which was stratified by age, sex, and state. This was an automated process and the assignment list was not visible to study staff or investigators. Active and placebo gel capsules, identical in appearance to ensure masking, were labelled A and B and the code was not available to study staff or investigators. Participants were asked to report occurrence of acute respiratory symptoms over the previous month via annual surveys, and a subset of participants completed 8-week respiratory symptom diaries in winter. As part of our process to maintain blinding, a random sample of participants was selected for analysis of survey data and a separate sample selected for analysis of diary data. Blood samples were obtained from a random sample of participants (about 450 per group per year) and serum 25-hydroxy vitamin D (25[OH]D) concentrations were measured to monitor adherence. We used regression models to estimate odds ratios (OR), rate ratios, and rate differences. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12613000743763. FINDINGS: Between Jan 13, 2014, and May 26, 2015, 421 207 invitations were sent, 40 824 people were interested in participating, and 21 315 participants were recruited and randomised. Of the 16 000 participants selected for potential analysis of survey data, 15 373 were included in the analysis; 295 in the vitamin D group and 332 in the placebo group who were missing data for all five annual surveys were excluded from the analysis. Of the 3800 selected for potential analysis of diary data, 3070 were invited to complete the diaries because 730 had already withdrawn. 2598 people were included in the analysis; 218 people in the vitamin D group and 254 in the placebo group were missing data and were therefore excluded from the analysis. In blood samples collected from randomly sampled participants throughout the trial, the mean serum 25(OH)D concentration was 114·8 (SD 30·3) nmol/L in the vitamin D group and 77·5 (25·2) nmol/L in the placebo group. Vitamin D supplementation did not reduce the risk of acute respiratory tract infection (survey OR 0·98, 95% CI 0·93 to 1·02; diary OR 0·98, 0·83 to 1·15). Analyses of diary data showed reductions in the overall duration of symptoms and of severe symptoms, but these were small and unlikely to be clinically significant. INTERPRETATION: Monthly bolus doses of 60 000 IU of vitamin D did not reduce the overall risk of acute respiratory tract infection, but could slightly reduce the duration of symptoms in the general population. These findings suggest that routine vitamin D supplementation of a population that is largely vitamin D replete is unlikely to have a clinically relevant effect on acute respiratory tract infection. FUNDING: National Health and Medical Research Council.
引用
- Pham H, Waterhouse M, Baxter C, et al. The effect of vitamin D supplementation on acute respiratory tract infection in older Australian adults: an analysis of data from the D-Health Trial. Lancet Diabetes Endocrinol. 2021. PMID: 33444565. doi:10.1016/S2213-8587(20)30380-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。